Preliminary Announcement:

The First International
China Biopharmaceutical Symposium

Beijing, China
21 - 25 September 2006

Sponsored and Hosted by:
The Chinese Pharmaceutical Association and Battelle Science and Technology International
International Management and Coordination by:
Applied Science & Analysis Inc., ASA

          This first symposium in China in this very exciting arena of biopharmaceuticals and the market will look at the opportunities and challenges primarily in the Chinese, US and EU markets and will, as a minimum, look at:
a. China's established and emerging biopharmaceutical companies and their capabilities and capacities to meet rapidly developing international product requirements
b. Strategic Partnering and Alliances
c. Distribution and Networking
d. Modernization of Facilities
e. GMP for Pharmaceuticals
f. Drug development in different countries.
g. Actual case studies in drug development, manufacture and distribution.
h. Testing from preclinical to final
i. An introduction to the regulatory process for bringing biopharmaceuticals to market featuring presentations on:
(1) the Chinese Regulatory Process
(2) the US Regulatory Process to include the FDA
(3) the EU Regulatory Process to include recognition and registration procedures and examples
(4) the Pacific Rim Countries and their Regulatory Processes.
j. Glossary and Terminology: China, US, EU, etc. Is there a significant difference? Impact?

          Included within the objectives will be an emphasis placed on vaccines from research to roadblocks to development, and strategies to overcome these obstacles, to pre-clinical and clinical trials in vaccine research, and to forging collaborations which would help move the whole process forward - rapidly. Although vaccines will be emphasized - this symposium will also be considering other important areas in biopharmaceutical research.

          A primary goal will be to surface and discuss the problems and to be able to exchange knowledge and information between developing and developed countries. The basic objective of ICBS is to have lively discussions, outstanding presentations and a camaraderie between all participants that will last from this meeting well out into the future.

          Some additional topics for presentations and discussions could include but not be limited to: (these will be expanded in the next ASA Newsletter 05-5)
a. Trends in vaccine requirements in developing countries and implications on regulation
b. Vaccine design - latest developments to include DNA vaccines
c. Actual case studies in infectious disease from SARS to HPAI
d. clinical trials and regulatory issues
e. non-vaccine issues and the regulatory arena
f. immunological data for vaccine and reagent design
g. modeling the artificial and virtual immune systems
h. immunotherapy and clinical trials

          The above topics are to be considered preliminary. The baskets of topics will be expanded with accepted recommendations from participants that fit within the general guidelines of the First ICBS.

          The call for papers and additional information on this First International China Biopharmaceutical Symposium (ICES) will be in the ASA Newsletter 05-5, October 2005, and will also be sent to the ASA/CBMTS members via the CBMTS Internet Update Network.

          Please note that, as with the CBMTS series, participation will be based on what each participant brings to this meeting that will help surface, illuminate and/or solve the problems or processes that may be required for the challenges and opportunities as outlined above. ASA will assist the Hosts and Sponsors in organizing and using the ICBS Science/Medicine Review Committee for review and acceptance of proposed presentations.

This ICBS program is guaranteed to be exceptional.